Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average of $4.42

Minerva Neurosciences, Inc. (NASDAQ:NERV) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.42 and traded as low as $3.28. Minerva Neurosciences shares last traded at $3.39, with a volume of 17,313 shares traded.

Wall Street Analysts Forecast Growth

NERV has been the subject of a number of recent analyst reports. HC Wainwright decreased their price objective on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a report on Thursday, May 2nd. StockNews.com initiated coverage on shares of Minerva Neurosciences in a report on Saturday. They issued a “sell” rating for the company.

Minerva Neurosciences Trading Up 0.9 %

The firm has a market capitalization of $23.70 million, a PE ratio of -0.76 and a beta of 0.15. The business’s 50 day simple moving average is $2.91 and its two-hundred day simple moving average is $4.42.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. As a group, equities research analysts anticipate that Minerva Neurosciences, Inc. will post -1.89 earnings per share for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.